Docetaxel is an anticancer agent that is used widely in the treatment of breast, prostate, gastric, head and neck, and lung cancer. In the product label for Taxotere (docetaxel), a variety of doses ranging from 60-100 mg/m² are approved for therapeutic use for these various indications, administered as a 1-hour infusion once every 3 weeks. Oradoxel Phase 1 studies are well underway in both New Zealand and the United States. These Phase 1 studies have been successful in identifying a dosing regimen suitable for a Phase 2 study, which we are planning to initiate in the first half of 2019.
Clinical Trial Pipeline
|Oradoxel||Territory||Indication||Sponsor/Partner||Pre-Clinical||Phase I||Phase II||Phase III|
|KX-ORADOX-003||United States||Solid Tumor||Athenex||